Skip to main content
. 2014 Aug 8;9(8):e103918. doi: 10.1371/journal.pone.0103918

Table 2. CTCs prevalence in recurrent/metastatic head and neck cancer patients.

Characteristic n (%)
Evaluable patients 53 (100)
CTCs+ pts at baseline 14 (26)
CTCs numbers at baseline Median CTCs 1
Mean CTCs ± SD 5±10
Range 1–43
CTCs+ pts at anytime 22 (41)
N. of CTCs determinations 1 16 (31)
2 21 (39)
3 5 (9)
4 11 (21)